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Aim. To investigate gene expression profile of human medullary breast carcinoma’s tumor-associated antigens
in different histological types of breast tumors. To analyze à correlation between alterations in gene expression
level and induction of immune response against the cor responding antigens. Methods. Real-time polymerase
chain reaction. Results. Differential gene expression profile of 6 (RAD50, HMGN2, RBPJ, PABPC4, BRAP,
DEK) medullary breast carcinoma tumor- associated antigens have been revealed in breast tumors of different
histological types. Correlation between changes in tumor-associated antigens gene expression level and
induction of immune response has not been found. Conclusions. The genes of human medullary breast
carcinoma tumor-associated antigens with differential expression pro- file in different histological types of breast
tumors are potential diagno- stic markers of breast cancer. Alteration of tumor-associated antigens gene
expression level is not a prelude to an immune response against their corresponding protein products.
Keywords: medullary breast carcinoma, tumor-associated antigens, immunoreactivity.
Introduction. Breast cancer is the most widespread
cancer type among women, remarkable for a high
mortality rate and mostly presented by the tumors of
epithelial origin – breast carcinomas (BCs). According
to the histopathological features, there are three
common types of tumors: invasive ductal breast
carcinoma (DBC, 50–80 % of all BCs), lobular breast
carcinoma (LBC, 5–15 %) and medullary breast
carcinoma (MBC, 1–7 %) [1]. This heterogeneity of
malignant breast tumors testifies to the urgency of
searching for new markers, required for the differential
diagnostics and therapy of this disease.
It is known that during carcinogenesis the human
immune system recognizes structurally altered, ampli-
fied or aberrantly expressed proteins (tumor-associated
antigens – TAA) as foreign entities. This may induce
cellular and/or humoral immune response [2]. The
study on the nature of immunogenicity of these
proteins as well as the determination of specific or
differential profiles of [the] TAAs gene expression in
different histological types of BC may become a basis
for the elaboration of novel and more efficient
approaches and means for diagnostics and therapy of
breast cancer. Besides, it will expand current views on
molecular mechanisms of malignant transformation
and antitumor immune response [1].
The application of novel highly efficient techno-
logies, in particular, phage display, SEREX (serolo-
gical identification of antigens by recombinant ex-
pression cloning), SERPA (serological proteome ana-
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lysis), and protein microarrays as well as meta-analysis
and scientific literature data allowed identifying a great
number of potential tumor-associated antigens [3]. In
our previous studies using the modified SEREX
method we have also identified tumor-associated anti-
gens of MBC [4]. However, their further application as
probable diagnostic biomarkers of neoplastic diseases
and targets for targeted tumor therapy should be
defined in detail. In particular, [the] TAAs expression
in different types of breast carcinomas and
immunogenicity in cancer patients should be studied
extensively, since presently it is not explicitly defined
why some autologous proteins become autoimmune
antigens in the course of tumor development. The
majority of authors state that the humoral immune
response is mostly directed to the proteins with altered
concentration, while the share of proteins with antigen
features acquired due to mutations is rather small [2, 5].
This item requires additional investigations.
The aims of this work were, firstly, to study the
expression patterns of genes encoding nine MBC-asso-
ciated antigens in breast tumors of different histologi-
cal types compared to conditional normal breast tissues
of women with fibrocystic disease, using the real-time
polymerase chain reaction (PCR) and, secondly, to
define a possible relation between the changes in the
level of gene expression and the induction of humoral
immune response to their protein products.
Materials and Methods. Tissues and blood serum
samples of patients. The surgical samples of normal
and breast cancer tissues were obtained in 2009–2011
in the Dnipropetrovsk Clinical Oncological Center
(Ukraine). The tissue samples were frozen in liquid
nitrogen immediately after surgical extraction and kept
until their application at –70 °C. 35 breast carcinoma
tissue samples were taken for study: invasive ductal
carcinoma (n = 22), invasive lobular carcinoma (n = 8)
and medullary carcinoma (n = 5). [The] Breast tissues
of patients with the fibrocystic disease (FCD) (n = 5)
were used as control (Table 1).
The histological type and grade of tumors were de-
fined by the histological and immunohistochemical
analysis (Dnipropetrovsk Clinical Oncological Cen-
ter).
The sera of cancer patients and healthy donors were
provided by the Dnipropetrovsk Clinical Oncological
Center and were used in the study (Table 1). The serum
samples were obtained by the standard phlebotomy
without anticoagulant and kept at – 20 °C with the
addition of glycerol to 50 %.
The protocol of the study was approved by the
Ethics committees of the Institute of Molecular
Biology and Genetics NAS of Ukraine and the
Dnipropetrovsk Clinical Oncological Center.
Real-time PCR. The extraction of total RNA,
treatment with DNAse and synthesis of cDNA. The
total RNA was extracted from the breast tumors and
normal tissues samples by guanidine-thiocyanate-
chloroform method using the standard protocol [6].
The amount and purity of the extracted total RNA were
defined using the Biomate 5 spectrophotometer (Ther-
mo Electron, USA) and 1 % formaldehyde-agarose de-
naturating gel-electrophoresis, respectively.
The aliquotes of total RNA (3 µg), extracted from
the tissue samples, were treated with DNAse I
according to the manufacturer’s protocol (Fermentas,
USA). The RevertAid Reverse Transcriptase Kit and
oligonucleotide primers Oligo(dT)18 were used to
synthesize cDNA in accordance to the standard
manufacturer’s protocol (Fermentas).
The real-time PCR was performed in iCycler iQ5
thermal cycler (Bio-Rad,) using SYBR Green I Master
Mix 2 (Fermentas, USA). The amplification was
performed with the following protocol: 95°C for initial
denaturation (60 s) and 45 two-stage amplification
cycles – denaturation at 95 °Ñ (10 s) and hybridization
of specific primers and their extension at 60°C (60 s).
The homogeneity and specificity of PCR products
were analyzed by electrophoresis in 1 % agarose gel as
well as by the presence of a sharp peak on the melting
curves of reaction products.
The calculations of the relative expression of target
genes normalized to the endogenous control and their
comparison in different samples were performed by
LinReg-Ct PCR method and Pfaffl’s equation [7]:
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where ETG and ERG – PCR efficiency for the target
and reference gene, respectively; CtTG – difference in
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Ct values, obtained for the target gene, between the
control and tumor samples; CtRG – difference in Ct va-
lues, obtained for the reference gene, between the con-
trol and tumor samples. The mean values of the corre-
sponding genes expression in five samples of breast tis-
sues of the patients with FCD were used as the control.
Enzyme-linked immunosorbent assay. The enzy-
me-linked immunosorbent assay of the number of anti-
bodies against the medullary breast carcinoma antigens
in the sera of breast cancer patients and healthy donors
was performed pursuant to the standard protocol [8].
Their recombinant analogues, obtained in our previous
studies, were used as the antigens [8].
Statistical data processing. The level of the target
gene expression in the tumor tissue sample was inter-
preted as changed – increased or decreased – if it was
threefold higher or lower, respectively, [3, 9] than the
mean relative expression level of the corresponding
gene in the control group of conditional normal breast
tissues of the patients with FCD according to the PCR-
analysis data [3, 9]. The reliable difference between the
frequencies of detecting the cases with the changed
gene expression in BC compared to conditional normal
tissues was determined using Pearson’s criterion (÷2).
The serum samples were considered positive if the
index of their optic density in the enzyme-linked im-
Characteristics
Number of samples
Tissue Blood serum
Experimental group (for tissue samples: 35 patients, mean age (years) SD 59.22 ± 12.7, age range 35–82;
for serum samples: 132 patients, mean age (years) SD 51.49 ± 17.2, age range 19–82)
Invasive ductal breast carcinoma 22 80
Invasive lobular breast carcinoma 8 23
Medullary carcinoma 5 9
Fibroadenoma – 20
Including tumors with known grade, % of the total: 86 82
Grade 1 0 7,3
Grade 2 22,2 33,9
Grade 3 77,8 59,8
Including ER status of tumors, % 76 52
Positive 78,1 71,1
Negative 21,9 28,9
Including PR status of tumors, % 76 52
Positive 62,5 61,5
Negative 37,5 38,5
Including HER-2/neu status of tumors, % 76 52
Positive 31,3 30,8
Negative 68,7 69,2
Including Ki-67 positive tumors, % 43 –
Including tumors with lymph node status, % of positive tumors 20 28,8
Control group (for tissue samples: five patients with FCD, mean age (years) SD 49.2 ± 10.04, age range 36–70;
for serum samples: 35 healthy donors, mean age (years) SD 39.2 ± 12.56, age range 17-60)
Note. SD – standard deviation; ER – estrogen receptor; PR – progesterone receptor; FCD – fibrocystic disease.
Table 1 The characteristics of the samples of tissues and blood sera of patients and the control group
munosorbent assay [8] exceeded the cut-off value,
defined as the mean value of the control sera of healthy
donors with the addition of three standard deviations.
Bioinformatical analysis. The database of SEREX-
antigens of CID (Cancer Immunome Database, URL:
http://ludwig-sun5.unil.ch/Cancer ImmunomeDB/)
was used for bioinformatical analysis of SEREX- an-
tigens.
The frequency of antigen detection in the cDNA
database of CID was determined using Excel software
(Microsoft Office, 2007).
Results and Discussion. The panel of nine target
antigens, selected for the analysis. Nine target antigens
were selected to study the expression profile in breast
carcinomas of different histological types compared to
normal breast tissues. The panel of nine target antigens
(P9TA) contained seven potential MBC tumor-asso-
ciated antigens (TAAs) (RAD50, FAM50A, HMGN2,
RBPJ, PABPC4, CTSL1, DEK), which were selected
on the basis of the phage allogenic screening of 41
MBC autoantigens [10] due to their reaction only with
the blood sera of breast cancer patients [11]. BRAP
and NaPi2B proteins were included in the analysis
because of the elevated level of their genes expression
in different tumors, including breast tumors (Table 2).
It should be noted that NaPi2B antigen is the target
of therapeutic monoclonal antibodies MX35, which are
under clinical trials for the treatment of ovarian car-
cinomas [16–19]. The detection of new sites of NaPi2B
expression in tumors expands a possible application of
MX35 antibodies for the therapy of patients with other
types of cancer, breast cancer in particular.
The determination of the relative gene expression
of target antigens at the mRNA level in different types
of breast carcinomas using real-time PCR. Real-time
PCR was used to determine the P9TA gene expression
profile in different types of breast tumors and in
non-tumor tissues.
The results of PCR-analysis are presented in Table
3, namely, the number of BC samples and tissues of the
patients with FCD with altered gene expression. It is
noteworthy that the expression levels of all nine target
antigens in the tissue samples of the patients with
fibrocystic diseases did not exceed the established
threshold, with the exception of one case of the de-
crease in SLC34A2 gene expression (Table 3).
The investigations demonstrated a significant
difference in the expression levels of three genes
(RAD50, DEK, BRAP) in BC compared to the breast
tissues of the patients with FCD. We established that
[the] DEK gene expression was three times higher in
BC compared to the control tissue and [the] expression
of genes RAD50 and BRAP was three times lower in
BC compared to the control tissue. This is in good
agreement with the previously reported literature data,
according to which the above-mentioned genes are
directly or indirectly involved in carcinogenesis.
We have also analyzed the P9TA genes expression
relative to the histological types of breast carcinomas
(Table 4 and Fig. 1).
The comparative analysis of the expression of
investigated genes in different histological types of
BCs and in the tissues of patients with FCD allowed us
to establish some group differences (Table 4). For
instance, we have found a significant elevation of the
expression levels of DEK and RBPJ genes as well as a
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Antigen Function Properties
RAD50 DNA double-strand break
repair[12]
medullary breast
carcinoma
SEREX-antigens [10]
FAM50A Unknown. Participation in
the cell cycle
HMGN2
Chromatin remodeling
RBPJ Intercellular
communication of Notch
signaling pathway
PABPC4 Regulation of mRNA
translation and stability
CTSL1 Intracellular and
extracellular proteolysis
DEK DNA replication and
repair, mRNA splicing
[13, 14]
BRAP Nuclear import of
proteins [15]
Most frequently
encountered antigen
in SEREX-antigen
database
NàP³2b
Transport of inorganic
phosphate into cells [16]
Breast cancer marker
[17]
Table 2
The characteristics of nine target antigens
reduction of the BRAP gene expression level in ductal
breast carcinomas compared to the normal breast
tissues. A significant decrease in the expression level
of four genes (RAD50, HMGN2, PABPC4 and BRAP)
was detected in the patients with LBC. The decrease of
HMGN2 and PABPC4 expression was revealed only in
this type of breast carcinoma. In medullary breast
carcinoma a significant increasing in the expression
level of DEK gene and decreasing in the expression
level of RAD50 gene compared to the control group
were identified.
Therefore, using the quantitative PCR-analysis, we
have established the differential expression profile for
six out of nine studied genes (RAD50, HMGN2, RBPJ,
PABPC4, BRAP and DEK) in different histological
types of BC (Fig. 2).
The comparative analysis of the immune reactivity
of blood sera of the breast cancer patients with
recombinant MBC antigens and the expression level of
the corresponding genes of these antigens in breast
tumors of the autologous patients was performed. In
our previous studies the presence of antibodies against
antigens of MBC, including RAD50, FAM50,
HMGN2, PABC4 and RBPJ was examined in blood
sera of the breast cancer patients and healthy donors
using the enzyme-linked immunosorbent assay [8].
The aim of current investigation is to find out a possible
correlation between the alterations in the expression of
five genes, RAD50, FAM50A, HMGN2, RBPJ and
PABPC4, and the existence of immune response to
their protein products. For this purpose the paired
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Gene
Number of tissue samples with altered mRNA expression
level
BC (n = 35) FCD (n = 5)
Increased Decreased
Increased or
decreased
RAD50 2 19* 0
FAM50A 16 6 0
RBPJ 15 1 0
PABPC4 6 12 0
HMGN2 4 10 0
CTSL1 4 7 0
DEK 21* 2 0
BRAP 1 24** 0
SLC34A2 11 2 One, reduced
Note. *p < 0,05; **p < 0,01.
Table 3
The analysis of expression of nine target genes in breast carcinomas
and tissues of patients with fibrocystic diseases (FCD)
Ãåí
Number of breast carcinoma samples
IDBC (n = 22) ILBC (n = 8) MBC(n = 5)
Increased Decreased Increased Decreased Increased Decreased
RAD50 1 8 1 7* 0 5*
FAM50A 10 4 1 0 2 1
RBPJ 13* 1 0 0 0 0
PABPC4 6 6 0 7* 0 0
HMGN2 4 3 0 5* 0 1
CTSL1 3 6 0 1 0 0
DEK 14* 1 3 1 5* 0
BRAP 1 16** 0 5* 0 2
SLC34A2 8 2 1 0 1 0
Note. IDBC – Invasive ductal breast carcinoma; ILBC – Invasive lobular breast carcinomaê; MBC – medullary breast carcinoma; *p < 0,05;
**p < 0,01.
Table 4
Profile of P9TA genes expression in breast carcinomas of different histological types
autologous tumor and blood sera samples, obtained
from 17 breast cancer patients, were analyzed.
Regardless of several coincidences of positive im-
mune response to the antigens RBPJ and RAD50 and
the changes in the expression of their genes (Table 5),
we can conclude that the altered genes expression does
not correlate with the existence of the immune response
to their correspondent antigens. Our data confirm the
assumptions of the authors in the work [3] that the
altered gene expression is not a mandatory prelude for
the formation of immune response against their protein
products [3]. The ultimate solution of the question on
the reasons of TAAs immunogenicity requires the
investigation of target antigens expression using a
larger number of BC samples, as well as the assessment
of protein abundance, as mRNA level does not always
correlate with the amount of the corresponding protein
product [20].
Therefore, we have demonstrated using the qua-
ntitative PCR method that three genes (DEK, RAD50
and BRAP) out of nine SEREX-antigens investigated
have significantly different expression levels in BC
tissues compared to the breast tissue of patients with
fibrocystic diseases.
We have identified the differential expression
profile of six genes (RAD50, HMGN2, RBPJ,
PABPC4, BRAP and DEK) in various histological
types of breast carcinomas compared to the tissues of
patients with FCD.
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Fig. 1 The analysis of the target gene expression RAD50 (a), RBPJ
(b), PABPC4 (c), HMGN2 (d), DEK (e) and BRAP (f) in tumor
samples of different histological types and control breast tissues.
The mean value of the relative level for the target gene expression at
the fibrocystic disease (FCD) at each chart corresponds to the
interception of Y- and X-axes. DBC –ductal breast carcinoma; LBC
– lobular breast carcinoma; MBC – medullary breast carcinoma;
*p < 0.05
The results of analysis of the SLC34A2 gene ex-
pression in different histological types of BCs testify to
its increased expression in approximately one third of
all breast carcinomas (11 out of 35) that is important for
the determination of the breast cancer patients pre-
sumably sensitive to the therapy with MX35 mono-
clonal antibodies [16].
We have not established any direct correlation
between the immune reactivity of five antigens
(RAD50, FAM50A, HMGN2, RBPJ ³ PABPC4) in the
sera of breast cancer patients and the altered expression
level of their genes in the autologous breast tumors.
Therefore, the data obtained allow suggesting that
the antigens RAD50, HMGN2, RBPJ, PABPC4,
BRAP and DEK are potential diagnostic markers and
possible targets for the therapy of certain cancer types,
which requires further studies using different metho-
dological approaches as well as a larger number of tis-
sues samples taken from the patients with BC of cer-
tain histological types.
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Ì. À.Øèÿí1, 2, Î. ². Êîñòÿíåöü1, 2, Î.Þ. Öóâàðºâ1, À. Â. Ñòîëÿðóê1,
Ñ. Â. Àíòîíþê3, Â. Â. Ô³ëîíåíêî1, Ð. Ã. Ê³ÿìîâà1
Îñîáëèâîñò³ åêñïðåñ³¿ ãåí³â ïóõëèíîàñîö³éîâàíèõ àíòèãåí³â ìå-
äóëÿðíî¿ êàðöèíîìè ìîëî÷íî¿ çàëîçè
ó ð³çíèõ òèïàõ ïóõëèí ìîëî÷íî¿ çàëîçè
1²íñòèòóò ìîëåêóëÿðíî¿ á³îëîã³¿ ³ ãåíåòèêè ÍÀÍ Óêðà¿íè
Âóë. Àêàäåì³êà Çàáîëîòíîãî, 150, Êè¿â, Óêðà¿íà, 03680
2ÍÍÖ «²íñòèòóò á³îëîã³¿» Êè¿âñüêèé íàö³îíàëüíèé óí³âåðñèòåò
³ìåí³ Òàðàñà Øåâ÷åíêà
Âóë. Âîëîäèìèðñüêà, 64/13, Êè¿â, Óêðà¿íà, 01601
3Äí³ïðîïåòðîâñüêèé êë³í³÷íèé îíêîëîã³÷íèé öåíòð
Âóë. Êîñì³÷íà, 21, Äí³ïðîïåòðîâñüê, Óêðà¿íà, 49100
Ìåòà. Äîñë³äèòè îñîáëèâîñò³ åêñïðåñ³¿ ãåí³â äåâ’ÿòè ïóõëèíîà-
ñîö³éîâàíèõ àíòèãåí³â ìåäóëÿðíî¿ êàðöèíîìè ìîëî÷íî¿ çàëîçè
(ÌÊÌÇ) ó ïóõëèíàõ ìîëî÷íî¿ çàëîçè ð³çíèõ ã³ñòîëîã³÷íèõ òèï³â ³
ïðîàíàë³çóâàòè ìîæëèâ³ñòü ³ñíóâàííÿ êîðåëÿö³¿ ì³æ çì³íàìè â
ð³âí³ åêñïðåñ³¿ ãåí³â òà íàÿâí³ñòþ ³ìóííî¿ â³äïîâ³ä³ ïðîòè
â³äïîâ³äíèõ àíòèãåí³â. Ìåòîäè. Ïîë³ìåðàçíà ëàíöþãîâî¿ ðåàêö³¿
ó ðåæèì³ ðåàëüíîãî ÷àñó. Ðåçóëüòàòè. Âèÿâëåíî äèôåðåíö³éíèé
ïðîô³ëü åêñïðåñ³¿ øåñòè (RAD50, HMGN2, RBPJ, PABPC4, BRAP ³
DEK) ç äåâ’ÿòè äîñë³äæóâàíèõ ãåí³â ó ð³çíèõ ã³ñòîëîã³÷íèõ òèïàõ
ïóõëèí ìîëî÷íî¿ çàëîçè. Êîðåëÿö³¿ ì³æ çì³íàìè â ð³âí³ åêñïðåñ³¿
ãåí³â òà íàÿâí³ñòþ ³ìóííî¿ â³äïîâ³ä³ ïðîòè â³äïîâ³äíèõ àíòèãåí³â
íå âñòàíîâëåíî. Âèñíîâêè. Ãåíè RAD50, HMGN2, RBPJ, PABPC4,
BRAP ³ DEK àíòèãåí³â ÌÊÌÇ, ÿê³ ìàþòü äèôåðåí- ö³éíèé
ïðîô³ëü åêñïðåñ³¿ ó ð³çíèõ ã³ñòîëîã³÷íèõ òèïàõ ïóõëèí ìîëî÷íî¿
çàëîçè, º ïîòåíö³éíèìè ä³àãíî- ñòè÷íèìè ìàðêåðàìè ðàêó ìîëî÷-
íî¿ çàëîçè. Âñòàíîâëåíî, ùî çì³íà åêñïðåñ³¿ äîñë³äæåíèõ ãåí³â íå
º îáî- â’ÿçêîâîþ óìîâîþ âèíèêíåííÿ ³ìóííî¿ â³äïîâ³ä³ ïðîòè ¿õí³õ
á³ëêîâèõ ïðîäóêò³â.
Êëþ÷îâ³ ñëîâà: êàðöèíîìà ìîëî÷íî¿ çàëîçè, ïóõëèíîàñîö³éî-
âàí³ àíòèãåíè, ³ìóíîðåàêòèâí³ñòü.
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Medullary carcinoma
Invasive ductal breast
carcinoma
Invasive lobular breast
carcinoma
DEK  RAD50 
BRAP 
RBPJ  HMGN2 
PABPC4 
Fig. 2 Block-scheme of the differential expression profile of six
genes in breast carcinoma of different histological types
Factor
Antigen
RAD50 FAM50A HMGN2 RBPJ PABPC4
Immune reactivity 5/17 0/17 0/17 2/17 0/17
Increased expression 1/17 6/17 2/17 4/17 1/17
Correlation with immune reactivity 0/17 0/17 0/17 1/17 0/17
Decreased expression 7/17 5/17 6/17 1/17 7/17
Correlation with immune reactivity 2/17 0/17 0/17 0/17 0/17
Table 5
Comparative analysis of sera reactivity and gene expression of tumor-associated antigens in 17 autologous blood sera and tumor tissues samples of
breast cancer patients
Ì. À. Øèÿí, Î. È. Êîñòÿíåö, Î. Þ. Öóâàðåâ, À. Â. Ñòîëÿðóê,
Ñ. Â. Àíòîíþê, Â. Â. Ôèëîíåíêî, Ð. Ã. Êèÿìîâà
Îñîáåííîñòè ýêñïðåñèè ãåíîâ îïóõîëå-àññîöèèðîâàííûõ
àíòèãåíîâ ìåäóëëÿðíîé êàðöèíîìû ìîëî÷íîé æåëåçû
â ðàçíûõ òèïàõ îïóõîëåé ìîëî÷íîé æåëåçû
Ðåçþìå
Öåëü. Èññëåäîâàòü îñîáåííîñòè ýêñïðåññèè ãåíîâ äåâÿòè îïó-
õîëü-àññîöèèðîâàííûõ àíòèãåíîâ ìåäóëëÿðíîé êàðöèíîìû ìîëî÷-
íîé æåëåçû (ÌÊÌÆ) â îïóõîëÿõ ìîëî÷íîé æåëåçû ðàçíûõ ãèñòî-
ëîãè÷åñêèõ òèïîâ è ïðîàíàëèçèðîâàòü âîçìîæíîñòü ñóùåñòâî-
âàíèÿ êîððåëÿöèè ìåæäó èçìåíåíèÿìè â óðîâíå ýêñïðåññèè ãåíîâ è
íàëè÷èåì èììóííîãî îòâåòà ïðîòèâ ñîîòâåòñòâóþùèõ àíòèãå-
íîâ. Ìåòîäû. Óðîâåíü ýêñïðåññèè ãåíîâ èçó÷àëè ìåòîäîì ïîëè-
ìåðàçíîé öåïíîé ðåàêöèè â ðåæèìå ðåàëüíîãî âðåìåíè. Ðåçóëü-
òàòû. Âûÿâëåí äèôôåðåíöèàëüíûé ïðîôèëü ýêñïðåññèè øåñòè
(RAD50, HMGN2, RBPJ, PABPC4, BRAP è DEK) èç äåâÿòè èññëå-
äóåìûõ ãåíîâ â ðàçëè÷íûõ ãèñòîëîãè÷åñêèõ òèïàõ îïóõîëåé ìî-
ëî÷íîé æåëåçû. Êîððåëÿöèè ìåæäó èçìåíåíèÿìè â óðîâíå ýêñïðåñ-
ñèè ãåíîâ è íàëè÷èåì èììóííîãî îòâåòà ïðîòèâ ñîîòâåòñòâóþ-
ùèõ àíòèãåíîâ íå îáíàðóæåíî. Âûâîäû. Ãåíû RAD50, HMGN2,
RBPJ, PABPC4, BRAP è DEK àíòèãåíîâ ÌÊÌÆ, èìåþùèõ äèô-
ôåðåíöèàëüíûé ïðîôèëü ýêñïðåññèè â ðàçëè÷íûõ ãèñòîëîãè÷åñêèõ
òèïàõ îïóõîëåé ìîëî÷íîé æåëåçû, ÿâëÿþòñÿ ïîòåíöèàëüíûìè
äèàãíîñòè÷åñêèìè ìàðêåðàìè ðàêà ìîëî÷íîé æåëåçû. Óñòàíîâ-
ëåíî, ÷òî èçìåíåíèå ýêñïðåññèè èññëåäîâàííûõ ãåíîâ íå ÿâëÿåòñÿ
îáÿçàòåëüíûì óñëîâèåì âîçíèêíîâåíèÿ èììóííîãî îòâåòà ïðî-
òèâ èõ áåëêîâûõ ïðîäóêòîâ.
Êëþ÷åâûå ñëîâà: êàðöèíîìà ìîëî÷íîé æåëåçû, îïóõîëü-àññî-
öèèðîâàííûå àíòèãåíû, èììóíîðåàêòèâíîñòü.
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